About this document "Gmail thread": summary

Summary of "Gmail thread" Document

This is an extensive email thread discussing the case of Marlo "Mo" Kwong, a 2-year-old boy with an ultra-rare, aggressive sarcoma. The conversation involves multiple medical professionals, data scientists, and AI specialists collaborating on his treatment strategy.

Key Medical Facts About Mo's Case:

Diagnosis Evolution:

• Born with a low-grade spindle cell tumor with myofibroblastic features
• Transformed into high-grade undifferentiated spindle cell sarcoma
• Primary driver: EGFR Internal Tandem Duplication (ITD) - also called EGFR-KDD (Kinase Domain Duplication)
• Location: Right brachial plexus, supraclavicular region, chest, mediastinum, T2-T3 spinal cord area
• Currently appears to be regional disease without distant metastases (no lung involvement after 26 months)

Molecular Profile:

• EGFR ITD (exons 18-25 duplication) - confirmed driver mutation
• Complex karyotype developed during transformation: losses of chromosomes 10 (PTEN), 13 (RB1), and 22
• No PDGFRB alteration (this was corrected in the thread - initial reports were inaccurate)
• Potential immunotherapy targets being explored: B7-H3, HER2, GD2, PRAME (not yet tested via IHC)

Current Treatment:

• Receiving chemotherapy + radiation + erlotinib (1st generation EGFR inhibitor)
• Showing partial response to current regimen

Main Discussion Points:

1. Treatment Strategy Debate:

• Should they switch from erlotinib to afatinib (2nd generation TKI)? Real-world evidence from a similar 2-year-old case in Spain showed good response
• Timing of CAR-T therapy (B7-H3 or HER2-directed) - consolidate now or continue successful regimen?
• Sequencing of therapies: cytoreduction → consolidation → maintenance

2. Diagnostic Refinement:

• Pathologist Allen Morris emphasized the importance of precise diagnosis before treatment planning
• Mayo Clinic pathologist expressed uncertainty: "I must confess I am really not at all certain what it is we are dealing with"
• Suggestion for additional blinded pathology reviews from other academic centers
• Discussion of whether this represents a "unicorn case" - diagnosis of exclusion

3. Advanced Testing & Models:

• Debate about functional drug testing (SageMedic, organoids, ChemoID)
• RNA sequencing data being analyzed by multiple teams
• Need for HER2 and B7-H3 IHC testing (critical priority)
• Consideration of CeGAT peptide vaccines vs CAR-T therapy

4. AI Analysis:

• Ian Maurer generated comprehensive AI reports using BioMCP tools and Claude
• Reports identified relevant clinical trials (HER2 CAR-T at Baylor - NCT04995003)
• AI analysis praised for thoroughness but noted to be "thin on diagnostic side" and biased toward NCCN guidelines/clinical trials

5. Novel Approaches Discussed:

• Integrin-targeted therapy (Dr. [removed] Sonenshein's work at Tufts) - speculative but potentially relevant
• Bispecific antibodies targeting multiple pathways
• [ID removed] vaccines and antisense oligonucleotides

Critical Next Steps Identified:

1. Immediate: Order HER2 and B7-H3 IHC testing
2. Assess tissue availability from October 2024 specimen (RNA failed QC twice)
3. Contact CAR-T trial sites: St. Jude and Baylor for pre-screening
4. Consider afatinib switch based on real-world evidence
5. Schedule cardiac echo (assess CAR-T eligibility)
6. Functional drug testing if fresh tissue available

Philosophical Approach:

The team is treating this as regional disease with curative intent rather than metastatic disease, which influences the treatment strategy toward aggressive local-regional control combined with targeted systemic therapy.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources referenced in thread: NCCN Guidelines, St. Jude Children's Research Hospital protocols, Mayo Clinic pathology consultations, Cancer Commons evidence summaries, clinical trial databases (NCT04995003)